Emergent BioSolutions Inc. (NYSE: EBS)

Emergent BioSolutions Inc. is a global life sciences company focused on providing preparedness and response solutions for accidental deliberate and naturally occurring public health threats. The company develops manufactures and distributes medical countermeasures vaccines and therapeutics for threats such as chemical biological radiological nuclear and explosives emerging infectious diseases and acute emergency care.

The company generates revenue from the sale of its commercial and medical countermeasure products from providing bioservices to external customers and from non dilutive contract and grant funding for research and development projects. Product sales include naloxone nasal sprays anthrax vaccines smallpox vaccines botulinum antitoxin and other immunotherapies.

The company operates through the following three segments: Commercial Product Segment MCM Products Segment and Services Segment.

• The Commercial Product Segment focuses on naloxone products NARCAN Nasal Spray and KLOXXADO Nasal Spray sold over the counter and by prescription in the United States and Canada to health departments law enforcement agencies community based organizations substance abuse centers federal agencies and consumers.

• The MCM Products Segment includes anthrax medical countermeasures smallpox medical countermeasures and other products such as ACAM2000 Anthrasil Bat BioThrax Cyfendus Ebanga Raxibacumab Tembexa and CNJ 016 sold primarily to the United States government international governments and non governmental organizations.

• The Services Segment provides bioservices including drug substance manufacturing drug product manufacturing fill finish packaging development services technology transfer process and analytical development using mammalian microbial viral and plasma platforms serving biopharmaceutical companies non governmental organizations and government agencies.

Emergent BioSolutions Inc. holds a market leading position in the public health preparedness sector supported by long term US government contracts and a diverse portfolio of medical countermeasures. The company faces competition from Jynneos SIGA Teva Padagis Amneal Amphastar Adamis Harm Reduction Therapeutics Thermo Fisher Lonza Fujifilm and other manufacturers of vaccines antitoxins and bioservices. Its competitive advantages include established manufacturing infrastructure strong relationships with federal agencies and a broad intellectual property portfolio.

Emergent BioSolutions Inc. sells to the U. S. Department of War the Biomedical Advanced Research and Development Authority BARDA the Department of Health and Human Services HHS the Assistant Secretary for Preparedness and Response ASPR Bavarian Nordic Syngene International Bora Pharmaceuticals Injectables Inc. Hikma Pharmaceuticals Inc. and Ridgeback Biotherapeutics. The company also serves state health departments law enforcement agencies community based organizations substance abuse centers federal agencies pharmacies consumers international governments and non governmental organizations.